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 Abstract 
 Background : A multicenter study conducted in Southeast 
Asia to derive reference intervals (RIs) for 72 commonly 
measured analytes (general chemistry, inflammatory 
markers, hormones, etc.) featured centralized measure-
ment to clearly detect regionality in test results. The 
results of 31 standardized analytes are reported, with the 
remaining analytes presented in the next report. 
 Method : The study included 63 clinical laboratories from 
South Korea, China, Vietnam, Malaysia, Indonesia, and 
seven areas in Japan. A total of 3541 healthy individuals 
aged 20 – 65 years (Japan 2082, others 1459) were recruited 
mostly from hospital workers using a well-defined common 
protocol. All serum specimens were transported to Tokyo 
at  − 80 ° C and collectively measured using reagents from 
four manufacturers. Three-level nested ANOVA was used 
to quantitate variation (SD) of test results due to region, 
sex, and age. A ratio of SD for a given factor over residual 
SD (representing net between-individual variations) (SDR) 
exceeding 0.3 was considered significant. Traceability of 
RIs was ensured by recalibration using value-assigned ref-
erence materials. RIs were derived parametrically. 
 Results : SDRs for sex and age were significant for 19 and 
16 analytes, respectively. Regional difference was signifi-
cant for 11 analytes, including high density lipoprotein 
(HDL)-cholesterol and inflammatory markers. However, 
when the data were limited to those from Japan, regional-
ity was not observed in any of the analytes. Accordingly, 
RIs were derived with or without partition by sex and 
region. 
 Conclusions : RIs applicable to a wide area in Asia were 
established for the majority of analytes with traceability to 
reference measuring systems, whereas regional partition-
ing was required for RIs of the other analytes. 
 Keywords:  common reference interval;  multicenter study; 
 nested ANOVA;  regionality;  standardization. 
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 Alb, albumin; ALP, alkaline phosphatase; ALT, alanine 
aminotransferase; AMY, amylase; AST, aspartate 
 aminotransferase; BC, Beckman Coulter; BMI, body mass 
index; C3, complement component 3; C4, complement 
component 4; Ca, total calcium; CK, creatine kinase; 
Cl, chloride; CRE, creatinine; CRM470, certified refer-
ence material 470; CRP, C-reactive protein; E2, estradiol; 
GGT,  γ -glutamyltransferase; Glu, glucose; Hb, hemo-
globin; HDL-C, high density lipoprotein- cholesterol; 
IgA, immunoglobulin A; IgG, immunoglobulin G; IgM, 
 immunoglobulin M; JCTLM, Joint Committee on Trace-
ability of Laboratory Medicine; JSCC, Japan Society of 
Clinical Chemistry; K, potassium; LD, lactate dehydro-
genase; LDL-C, low density lipoprotein-cholesterol; 
MCV, mean corpuscular volume; Na, sodium; RI, refer-
ence interval; TCho, total cholesterol; Tf, transferrin; TG, 
 triglycerides; TTR, transthyretin (prealbumin); UA, uric 
acid. 
 *Corresponding author: Kiyoshi Ichihara , MD, PhD, Department of 
Clinical Laboratory Sciences, Faculty of Health Sciences, Yamaguchi 
University Graduate School of Medicine, Minami-Kogushi 1-1-1, Ube, 
755-8505 Japan, Phone:  + 81 836 222884, Fax:  + 81 836 355213, 
E-mail:  ichihara@yamaguchi-u.ac.jp 
 Ferruccio Ceriotti:  Diagnostica e Ricerca San Raffaele, San Raffaele 
Scientific Institute, Milan, Italy
  Tran Huu Tam:  Center for Standardization and QC in Medical 
Laboratories, Ho Chi Minh City, Vietnam
Authenticated | ichihara@yamaguchi-u.ac.jp author's copy
Download Date | 4/19/13 10:31 AM
2      Ichihara et al.: Multicenter study on reference values in Asia
 Shigeo Sueyoshi:  Clinical Laboratory, Chiba Cardiovascular Center, 
Ichihara, Japan
 Priscilla M.K. Poon:  Department of Chemical Pathology, Chinese 
University of Hong Kong, Hong Kong
 Mee Ling Thong:  Department of Laboratory and Blood Services, 
National Heart Institute, Kuala Lumpur, Malaysia
 Yasushi Higashiuesato:  Clinical Laboratory, University of the 
Ryukyus, Graduate School of Medicine, Okinawa, Japan
 Xuejing Wang:  Department of Clinical Laboratory Medicine, Peking 
University First Hospital, Beijing, China
 Hiromi Kataoka:  Center of Medical Information Science, Kochi 
Medical School, Kochi, Japan
 Akemi Matsubara:  Clinical Laboratory, Hiroshima University 
Hospital, Hiroshima, Japan
 Shu-Chu Shiesh:  Department of Medical Laboratory Science and 
Biotechnology, National Cheng Kung University, Tainan, Taiwan
 Dewi Muliaty:  Prodia Clinical Laboratory, Jakarta, Indonesia
 Jeong-Ho Kim:  Department of Laboratory Medicine, Yonsei 
University College of Medicine, Seoul, Korea
 Masakazu Watanabe:  Beckman Coulter Japan Co., Tokyo, Japan
 Christopher W. K. Lam:  Macau Institute for Applied Research in 
Medicine and Health, Macau University of Science and Technology, 
Macau
 Lothar Siekmann:  Institute of Clinical Chemistry and Pharmacology, 
Universitätsklinikum, Bonn, Germany
  Joseph B. Lopez:  Department of Biomedical Sciences, MAHSA 
University College, Kuala Lumpur, Malaysia
 Mauro Panteghini:  Centre for Metrological Traceability in Laboratory 
Medicine (CIRME), University of Milano, Milan, Italy 
 Introduction 
 The global standardization of laboratory tests for major 
analytes has been achieved by the efforts of the Interna-
tional Federation of Clinical Chemistry and Laboratory 
Medicine (IFCC) and its national member organizations 
[ 1 ]. However, reference intervals (RIs) still frequently 
differ from one laboratory to another. According to the 
directive on in vitro diagnostic medical devices of the 
European Union [ 2 ], diagnostic manufacturers are now 
requested to supply their clients with appropriate RIs 
attached to their reagents, and the ISO 15189 standard for 
clinical laboratory accreditation claims that the labora-
tory should periodically re-evaluate its RIs [ 3 ]. However, 
despite these requirements, there have been only a 
limited number of attempts to conduct appropriate mul-
ticenter studies to achieve this goal [ 4 − 6 ]. Most studies to 
date were conducted by gathering test results of healthy 
donors ’ specimens measured at each participating labo-
ratory. This relies on two main assumptions: comparabil-
ity of assay results across different laboratories and lack 
of regionality in test results. Validation of these assump-
tions, however, is not easy and thus, the interpretation of 
RIs is not straightforward. 
 One multicenter study was conducted in six Asian 
cites by the Committee on Plasma Proteins (C-PP) of 
the IFCC Scientific Division (IFCC-SD) in 2000 to derive 
common reference intervals for 14 major serum proteins 
[ 7 ] whose standardization had almost been achieved 
by the availability of certified reference material 470 
(CRM470) produced under the direction of the C-PP [ 8 ]. 
This study adopted a different approach, that of centra-
lized measurement, by sending all of the specimens to 
one center in Japan and measuring them collectively in 
a single laboratory. Unexpectedly, it revealed large inter-
region variation for many analytes belonging to the class 
of inflammatory markers, such as IgG, C3, and CRP [ 7 ]. To 
confirm these findings, another study was conducted in 
2006 with the participation of six other centers belong-
ing to the Asia Pacific Federation of Clinical Biochemistry 
(APFCB) [ 9 ]. A total of 560 healthy individuals, mainly 
those working in clinical laboratories, donated blood to 
allow measurement of 32 common analytes (22 biochemi-
cal analytes and 10 proteins). This second survey con-
firmed significant regionality in about one third of the 
analytes examined. 
 Prompted by these observations, this present third 
study was planned jointly by the C-PP, the Committee 
on Reference Intervals and Decision Limits (C-RIDL) 
of the IFCC-SD, and by the Scientific Committee of the 
APFCB. The primary goal was to verify the possibility of 
establishing common RIs (i.e., RIs that can be applied 
to the entire population, independently from the ana-
lytical method in use [ 10 ]) for the standardized ana-
lytes by ensuring traceability of test results. To do this, 
we collected samples from several relatively homog-
enous groups of individuals in Japan and in Southeast 
Asia together with a considerable amount of informa-
tion allowing us to put in evidence regarding possible 
effects due to environment and/or lifestyle. Thus, we 
were able to investigate biological sources of variations 
in each analyte, including the presence of differences in 
RIs related to geographical areas (regionality). Our work 
was not limited to well-standardized analytes but also 
included non-standardized analytes mostly measured by 
immunoassays, such as tumor markers, and hormones. 
To achieve these goals, we again adopted the central-
ized measurement approach to eliminate assay-related 
variations. For clarity of presentation, we report herein 
the results limited to 31 standardized analytes and leave 
results of other analytes to the next report. 
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 Materials and methods 
 Participating centers 
 Invitations to the study together with its protocol were sent to clinical 
laboratories of major hospitals and commercial laboratories in coun-
tries belonging to the APFCB. Fift een laboratories located in Seoul, 
Beijing, Taipei, Tainan, Ho Chi Minh City, Kuala Lumpur, Hong Kong, 
Macau, and Jakarta accepted the invitation. In Japan, collaboration 
was obtained nationwide from 47 laboratories. All laboratories are 
listed in the Acknowledgments. 
 Target population and sample size 
 We limited the population mainly to those working in clinical labora-
tories or hospitals to eliminate the potential infl uence of diff erences 
in job profi les on the test results. A minimum sample size from each 
local area was set at 120 samples to gain adequate statistical power 
to detect diff erences among areas. Usually two or more laboratories 
from each city collaborated to achieve the target number. The age 
range of donors was set at 20 – 65 years. The utmost eff ort was made 
to ensure an even distribution of age and an equal male to female 
ratio. 
 The following exclusion criteria were applied at the time of re-
cruitment: 1) body mass index (BMI)   ≥  28 kg/m 2 ; 2) average daily con-
sumption of ethanol   ≥  75 g [this amount of alcohol intake is rather 
high, but it was decided to leave it as a general criterion to evaluate 
the eff ect of alcohol assumption and to adopt specifi c exclusion cri-
teria for analytes known to be infl uenced by alcohol intake (e.g., ALT, 
GGT, etc.)], 3) cigarette smoking  > 20/day, 4) regular medication for 
chronic disease (diabetes mellitus, hypertension, hyperlipidemia, 
allergic disorders, etc.), 5) recent (  ≤  2 weeks) recovery from acute ill-
ness or surgery requiring hospitalization, 6) known hepatitis B or C 
virus carrier, and 7) pregnancy or within 1 year aft er childbirth. 
 For analysis of sources of variation for each analyte, a health-
status survey was conducted via questionnaire to obtain information 
on BMI, ABO blood type, eating patterns, recent episodes of infection 
or allergy, menstrual status, and other factors. Written informed con-
sent was obtained from each volunteer. The specimens, the test re-
sults, and questionnaires were processed anonymously by assigning 
sequential numbers on arrival to each individual. Aft er completion of 
measurement for major analytes, the test results together with newly 
derived sex-specifi c RIs were reported confi dentially. 
 The study was approved by the Ethical Committee of Yamaguchi 
University Graduate School of Medical Sciences in December, 2008. 
The other collaborative laboratories followed their own rules in tak-
ing part in the study. 
 Collection of blood samples 
 Prior to blood sampling, each volunteer was requested to avoid stren-
uous physical exertion/exercise during the preceding 4 days, exces-
sive eating or drinking the night before, and to fast overnight at least 
for 10 h. 
 Venipuncture was done between 7 am and 10 am aft er the donor 
sat quietly for at least 15 min to avoid variations of test results due 
to physical activity and postural infl uence. Blood in the amount of 
17 mL was drawn from each donor. All participating laboratories re-
ceived the same blood drawing set containing the vacuum sampling 
system, provided by Becton-Dickinson Corp. (BD), (Franklin Lakes, 
NJ, USA), including BD Vacutainer SST tubes (capacity: 8.5 mL) con-
taining a clot-activator and CryoTube cryovials (capacity: 4.8 mL) 
(Nunc, Roskilde, Denmark). Aft er blood collection, the tubes were 
rocked 180 ° at least fi ve times, and centrifugation for serum sepa-
ration was done within 2 h of collection. The separated serum was 
transferred and aliquoted immediately to the freezing vials for stor-
age at  − 80 ° C. As an adjunct test, a peripheral blood count (CBC) in 
EDTA-2K blood was performed locally. The results were used as crite-
ria to exclude those who were anemic. The CBC test results were ob-
tained from 1978 individuals in laboratories that used the Beckman-
Coulter hematology analyzer [Beckman Coulter Inc. (BC), Brea, CA, 
USA] for their routine assays. 
 Target analytes and measurements 
 Seventy-two analytes (lipids, electrolytes, enzymes, tumor markers, 
hormones, vitamins, etc.) were targeted for collective measurements. 
Assay methods, reference materials, and their precisions for the 31 
standardized analytes included in this report are listed in  Table 1 . 
The auto-analyzer used in the centralized assays was the UniCel DxC 
(BC). Enzyme activities except for amylase (AMY) were measured in 
duplicate, one by the IFCC- and the other by JSCC (Japan Society for 
Clinical Chemistry)-recommended method. The assays were done at 
BC Japan ’ s Central Laboratory located in Ariake, Tokyo, using the 
manufacturer ’ s reagents, calibrators, and controls, unless otherwise 
indicated. 
 For quality control monitoring, a set of four fresh-frozen pooled 
sera from healthy individuals, stored aliquoted at  − 80 ° C, were used 
to evaluate imprecision of assays. The average results of imprecision 
using these samples are listed in  Table 1 . 
 Specimen transportation 
 Serum specimens were packed in a styrene foam box container fi lled 
with dry ice and transported to the central laboratory by a domestic 
express courier service within Japan. Outside Japan, the sample con-
tainers were picked up from each laboratory by the coordinator of 
this study and transported to Japan by airplane, carried as check-in 
baggage. 
 Verification of traceability 
 Reference methods and/or materials for the 31 analytes are available 
in the database of the Joint Committee on Traceability of Laboratory 
Medicine (JCTLM). We checked traceability to the corresponding ref-
erence system using the materials or methods listed in  Table 1 . When 
reference laboratory services were involved (enzymes and hormones), 
a set of three fresh-frozen ( − 80 ° C) pooled sera for each enzyme (AST, 
ALT, LD, GGT, and CK), or fi ve to nine levels of lyophilized specimens 
(for the four steroid hormones), were fi rst value-assigned by the ref-
erence laboratories (see Acknowledgments) and then used to check 
alignment of the analytical systems used for obtaining reference 
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 Table 1   List of assay methods and assay imprecision near the mid-normal ranges. 




 Alb  Albumin  Timed endpoint bromcresol purple 
method 
 Beckman Coulter  CRM470  1.53  1.37 
 Urea  Urea  Enzymatic rate method  Beckman Coulter  JCCRM521  1.54  2.46 
 UA  Uric acid  Timed endpoint uricase POD method  Beckman Coulter  JCCRM521, 21  0.68  1.11 
 CRE  Creatinine  Enzymatic method  Beckman Coulter  JCCRM521  2.41  2.97 
 Na  Sodium  Indirect potentiometry  Beckman Coulter  JCCRM111, 321  0.22  0.91 
 K  Potassium  Indirect potentiometry  Beckman Coulter  JCCRM111, 321  0.46  0.89 
 Cl  Chloride  Indirect potentiometry  Beckman Coulter  JCCRM111, 321  0.25  0.72 
 Ca  Total serum calcium  Indirect potentiometry  Beckman Coulter  JCCRM321  0.57  1.26 
 Glu d  Glucose  Timed endpoint hexokinase method  Beckman Coulter  JCCRM521  0.77  1.26 
 TCho  Total cholesterol  Timed endpoint enzyme colorimetry  Beckman Coulter  JCCRM223  1.20  0.74 
 TG  Triglyceride  Timed endpoint enzyme colorimetry  Beckman Coulter  JCCRM223, 224  1.21  0.80 
 HDL-C  HDL-cholesterol  Timed endpoint direct method  Beckman Coulter  JCCRM223, 224  0.99  1.61 
 LDL-C  LDL-cholesterol  Timed endpoint direct method  Beckman Coulter  JCCRM224  1.17  1.31 
 AST  Aspartate 
aminotransferase 
 IFCC recommended method  Beckman Coulter  JCTLM ref lab b  2.22  0.73 
 AST-JSCC   JSCC recommended method  Beckman Coulter  JCCLS CRM-001b  3.40  0.37 
 ALT  Alanine aminotransferase  IFCC recommended method  Beckman Coulter  JCTLM ref lab b  2.88  1.27 
 ALT-JSCC   JSCC recommended method  Beckman Coulter  JCCLS CRM-001b  3.44  0.44 
 LD  Lactate dehydrogenase  IFCC recommended method  Beckman Coulter  JCTLM ref lab b  1.42  0.29 
 LD-JSCC   JSCC recommended method  Beckman Coulter  JCCLS CRM-001b  1.93  0.80 
 ALP  Alkaline phosphatase  IFCC reccommended method  Beckman Coulter  –  1.91  2.60 
 ALP-JSCC   JSCC recommended method a  Beckman Coulter  JCCLS CRM-001b  1.45  0.83 
 GGT  γ -glutamyltransferase  IFCC recommended method  Beckman Coulter  JCTLM ref lab b  2.14  4.63 
 GGT-JSCC   JSCC recommended method  Beckman Coulter  JCCLS CRM-001b  1.60  1.86 
 CK  Creatine kinase  IFCC recommended method  Beckman Coulter  JCTLM ref lab b  0.86  0.88 
 CK-JSCC   JSCC recommended method  Beckman Coulter  JCCLS CRM-001b  1.22  0.91 
 AMY  Amylase  JSCC recommended method  Beckman Coulter  JCCLS CRM-001b  0.89  0.61 
 IgG  Immunoglobulin G  Turbidimetric method  Nittobo Medical  CRM470  0.63  1.76 
 IgA  Immunoglobulin A  Turbidimetric method  Nittobo Medical  CRM470  1.76  3.40 
 IgM  Immunoglobulin M  Turbidimetric method  Nittobo Medical  CRM470  1.09  1.46 
 C3  Complement component 3  Turbidimetric method  Beckman Coulter  CRM470  0.81  1.77 
 C4  Complement component 4  Turbidimetric method  Beckman Coulter  CRM470  2.04  2.82 
 CRP  C-reactive protein  Latex immunoturbidimetric method  Nittobo Medical  CRM470  0.68  2.29 
 TTR  Transthyretin(prealbumin)  Turbidimetric method  Beckman Coulter  CRM470  1.72  2.98 
 Tf  Transferrin  Turbidimetric method  Beckman Coulter  CRM470  2.65  3.61 
 Testo  Testosterone  Chemiluminescent enzyme immunoassay  Beckman Coulter  JCTLM ref lab c  2.70  2.38 
 E2  Estradiol  Chemiluminescent enzyme immunoassay  Beckman Coulter  JCTLM ref lab c  7.43  6.40 
 Prog  Progesterone  Chemiluminescent enzyme immunoassay  Beckman Coulter  JCTLM ref lab c  5.98  6.35 
 Cortisol  Cortisol  Chemiluminescent enzyme immunoassay  Beckman Coulter  JCTLM ref lab c  2.17  1.94 
 a Kinetic rate method (using AMP buffer);  b used for recalibration were pooled sera of three concentrations, which were prepared for each 
enzyme, and values were assigned by the reference measurement system (RMS);  c used for recalibration were lyophilized specimens of five 
to eight concentrations that were value-assigned by RMS;  d The analyte was measured in specimens collected without addition of sodium 
fluoride. The result was used as one of the exclusion criteria. 
values. Particularly, recalibration of test results was made based on 
the experimental relation between the assigned values and the test 
results (measured on three separate days, each in triplicate) obtained 
at BC ’ s laboratory in Tokyo. When there were more than two levels of 
reference materials, the regression line to be used for recalibration 
was computed by use of the reduced major-axis regression method 
[ 11 ,  12 ]. For reference materials that have just a single level, the ratio 
of the assigned value to average measured values was used for rec-
alibration. 
 Statistical analyses 
 Analyses for sources of variations and partitioning 
criterion 
 The test results were evaluated by use of the same statistical proce-
dures employed in the previous study [ 9 ]. In brief, sources (factors) of 
variations were analyzed by three-level nested ANOVA (3N-ANOVA). 
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The factors considered were sex, region, age, and BMI. Primarily, the 
fi rst three factors were analyzed; then, aft er separating data by sex, 
the analyses using the last three factors were performed. The magni-
tude of variation due to each factor is expressed as a standard devia-
tion (SD): i.e., between-region SD (SD reg ), between-sex SD (SD sex ), and 
between-age SD (SD age ). In the analysis, regions were categorized into 
14 areas (7 within Japan, 7 outside Japan), age was stratifi ed into four 
groups (20 – 29, 30 – 39, 40 – 49, and 50 – 65 years), and BMI was sepa-
rated into six categories by setting the following boundary values: 18, 
20, 22, 24, and 26 kg/m 2 . 
 The relative magnitude of each variable to that of the residual 
SD representing a net between-individual SD (SD net-btw-indiv ), which 
roughly corresponds to one quarter of the width of the RI obtained 
aft er adjusting for the infl uence of age and sex, was computed as the 
SD ratio (SDR) by the following formula: 
 SDR factor = SD factor /SD net-btw-indiv 
 An SDR of   ≥  0.3 was regarded as high, requiring partition of 
reference values by the factor [ 13 ]. Meanwhile, an SDR between 0.25 
and 0.29 was considered moderate in degree. In the above computa-
tion, when the distribution of the test results was skewed and had a 
long upper tail, the values were logarithmically transformed before 
3N-ANOVA was applied (as indicated in  Table 2 ). In these cases, the 
back-transformed SD described elsewhere [ 9 ] was used in the above 
equation. In the analysis of regionality, when computing SDR for re-
gion (SDR reg ), test results obtained within Japan were all combined, 
as were those from the two cities in Taiwan, and those from Hong 
Kong and Macau, respectively, as single regions. Meanwhile, test 
results from Seoul, Beijing, Ho Chi Minh City, Kuala Lumpur, and 
Jakarta were treated as separate regions; thus, the number of regions 
served for the analysis of SDR reg was eight in all. 
 Derivation of reference intervals 
 As a preliminary step to select appropriate reference individuals, 
those who had extreme values in analytes related to obesity, anemia, 
infl ammation, and thyroid dysfunction as follows were excluded be-
fore the derivation of RIs: Hb   ≤  96 or   ≥  180 g/L, MCV   ≤  70 fL, UA   ≤  95 
or   ≥  536  μ mol/L (  ≤  1.6 or   ≥  9.0 mg/dL), TG  > 3.96 mmol/L (350 mg/dL), 
Glu  > 6.95 mmol/L (125 mg/dL), TCho  > 8.04 mmol/L (311 mg/dL), 
ALT  > 101 U/L, GGT  > 140 U/L, AST  > 80 U/L, CK  > 800 U/L, CRP 
 > 20 mg/L, FT4  > 23.17 pmol/L (1.8 ng/dL), and TSH  > 14 mU/L. As for 
BMI, 65 (1.8%) individuals exceeded the upper limit of 28 kg/m 2 set at 
the time of recruitment. In consideration of the imprecision of BMI 
and the availability of related information indicating obesity, the fi -
nal exclusion criterion was set as a BMI of   ≤  14 or   ≥  30 kg/m 2 . Thus, 21 
individuals were excluded by these BMI extremes. 
 The RIs were derived parametrically by use of modifi ed Box-Cox 
transformation [ 14 ], which invariably succeeds in transforming refe-
rence values into those of Gaussian distribution as long as there are 
not many results that are below the detectable limits [ 13 ]. As a tertiary 
exclusion step to further refi ne the reference values, an iterative ap-
proach called the  ‘ latent abnormal values exclusion ’ (LAVE) method 
was applied for the actual derivation of the RIs [ 7 ,  13 ,  14 ]. As exclusion 
criteria, the RIs of the following 13 analytes were used: Alb, Glb, UA, 
Glu, AST, ALT, LD, GGT, CK, TG, HDL-C, LDL-C, and CRP. In short, 
the initial RIs were derived analyte by analyte independently of the 
results of the others. From the second iteration, the RIs for the above 
exclusion criteria analytes obtained at the previous cycle of iteration 
were used to exclude individuals who had abnormal results in ana-
lytes other than the one being evaluated. In applying the exclusion 
criteria, the RIs were extended on both ends by 5% of the interval, 
or (upper limit – lower limit)  × 0.05. Therefore, when the test results 
are normally distributed, results outside of the mean ± 2.16 SD (total 
of 3% on two tails) are regarded as abnormal. This adjustment was 
made to avoid excluding too many individuals unnecessarily. The 
computation was continued until the RIs of all the analytes became 
stable. 
 Statistical analyses and 3N-ANOVA was performed with general 
purpose statistical soft ware StatFlex for Windows Ver. 6.0 (Artech, 
Osaka, Japan). Original soft ware named  ‘ Reference Master ’ devel-
oped by the fi rst author was employed to derive RIs based on the 
LAVE principle and parametric methods. 
 Results 
 Profile of the subjects 
 The demographic profile of the participants from each city 
is summarized in  Table 3 . The tabulation was made after 
deleting those with extreme values based on the criteria 
described in the Methods. As a whole, there were more 
females than males (1959 vs. 1582). The information on 
ethnicity was not obtained in Japan, Korea, and China 
with known homogeneity of the target population in the 
medical facilities involved. The ethnic composition in other 
countries was as follows: in Kuala Lumpur: Chinese 36%, 
Malay 45%, Indian 13%; in Ho Chi Minh City:  Vietnamese 
(Kinh) 98%; in Jakarta: Malay 86%, Chinese 13%. 
 The between-region differences in age, BMI, and 
levels of smoking and alcohol use were analyzed by 
one-way ANOVA separately for each sex. The ratios of pure 
component of between-region SD divided by residual SD 
representing between-individual SD in males (females) 
were 0.10 (0.10) for age, 0.21 (0.22) for BMI, 0.18 (0.17) for 
smoking, and 0.63 (0.55) for alcohol, respectively. The 
ratio has the same implication as the SDR described above 
as a means of computing the magnitude of a given vari-
ation source. If we set 0.30 as the practically significant 
effect size of each factor, only the level of alcohol use was 
apparently different across the Asian cities, reflecting dif-
ferences in religion and culture. 
 The job profile of the reference individuals (n = 3314) 
after the selection process is shown in Supplementary Table 
1 which accompanies the article at http://www.degruyter.
com/view/j/cclm.2013.51.issue-7/issue-files/cclm.2013.51.
issue-7.xml. Those individuals who belonged to the 
medical institutions and those who did not accounted for 
83.4% (62.9% – 91.5%) and 9.9% (2.7% – 27.3%), respectively, 
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 Table 3   Demography of the healthy individuals recruited. 
 Male 
 




 Age  BMI  Tobacco  Alcohol 
 Me  95%CI  Me  95%CI  No  Yes  Rare  Yes 
 North Japan  157  146  38  23 – 60  22.3  17.7 – 27.8  97  49  51  95 
        (66%)  (34%)  (35%)  (65%) 
 Tokyo  130  119  36  22 – 59  22.4  17.3 – 27.5  87  31  46  72 
        (74%)  (26%)  (39%)  (61%) 
 Central Japan  127  109  41  23 – 58  22.3  17.6 – 27.8  81  28  45  64 
        (74%)  (26%)  (41%)  (59%) 
 Osaka  116  110  40  21 – 61  22.4  17.9 – 27.8  85  25  33  77 
        (77%)  (23%)  (30%)  (70%) 
 West Japan  185  176  39  23 – 60  22.0  18.4 – 26.8  129  46  59  116 
        (74%)  (26%)  (34%)  (66%) 
 South Japan  136  127  36  20 – 60  22.0  17.7 – 27.9  76  47  48  76 
        (62%)  (38%)  (39%)  (61%) 
 Okinawa  96  92  35  21 – 59  22.8  17.9 – 27.7  69  23  26  66 
        (75%)  (25%)  (28%)  (72%) 
 Seoul  60  56  38  23 – 58  22.8  19.2 – 27.5  36  20  24  32 
        (64%)  (36%)  (43%)  (57%) 
 Beijing  59  51  36  23 – 58  24.4  17.3 – 28.2  38  13  41  10 
        (75%)  (25%)  (80%)  (20%) 
 Taiwan  145  137  36  22 – 60  22.8  17.4 – 27.3  118  19  121  16 
        (86%)  (14%)  (88%)  (12%) 
 Hong Kong  118  105  41  23 – 59  23.7  18.2 – 27.5  90  15  90  15 
        (86%)  (14%)  (86%)  (14%) 
 HCMC  131  107  33  22 – 58  22.1  17.6 – 27.7  79  28  70  36 
        (74%)  (26%)  (66%)  (34%) 
 Kuala Lumpur  63  52  31  20 – 60  23.2  17.8 – 28.4  37  15  49  0 
        (71%)  (29%)  (100%)  (0%) 
 Jakarta  59  51  39  24 – 63  23.8  18.4 – 28.7  37  14  51  0 
        (73%)  (27%)  (100%)  (0%) 
 Sum  1582  1438  37  21 – 59  22.6  17.7 – 27.8  1059  373  754  675 
        (74%)  (26%)  (53%)  (47%) 
 Female 
 




 Age  BMI  Tobacco  Alcohol  Menopause 
 Me  95%CI  Me  95%CI  No  Yes  Rare  Yes  No  Yes  ? 
 North Japan  186  184  37  22 – 59  19.8  16.4 – 26.1  160  23  107  77  144  37  3 
        (87%)  (13%)  (58%)  (42%)  (80%)  (20%)  
 Tokyo  183  177  35  22 – 58  20.9  17.4 – 28.1  161  16  109  68  150  23  4 
        (91%)  (9%)  (62%)  (38%)  (87%)  (13%)  
 Central Japan  188  186  36  22 – 57  19.8  16.2 – 24.9  176  9  116  69  150  29  7 
        (95%)  (5%)  (63%)  (37%)  (84%)  (16%)  
 Osaka  136  133  38  21 – 60  20.8  16.4 – 26.7  119  5  84  42  100  24  9 
        (96%)  (4%)  (67%)  (33%)  (81%)  (19%)  
 West Japan  232  224  37  23 – 60  19.8  16.6 – 24.6  217  7  144  79  172  45  7 
        (97%)  (3%)  (65%)  (35%)  (79%)  (21%)  
 South Japan  113  107  37  20 – 58  20.1  17 – 25.9  98  9  78  29  89  16  2 
        (92%)  (8%)  (73%)  (27%)  (85%)  (15%)  
 Okinawa  97  96  35  21 – 57  20.7  17.6 – 26.6  94  1  58  37  86  9  1 
        (99%)  (1%)  (61%)  (39%)  (91%)  (9%)  
 Seoul  73  71  38  22 – 61  20.9  17.7 – 27.6  69  2  54  16  57  11  3 
        (97%)  (3%)  (77%)  (23%)  (84%)  (16%)  
 Beijing  83  78  39  22 – 58  22.0  17.6 – 26.9  76  2  77  1  59  18  1 
        (97%)  (3%)  (99%)  (1%)  (77%)  (23%)  
 Taiwan  190  175  36  23 – 59  20.7  16.8 – 27.3  174  0  174  1  145  30  0 
        (100%)  (0%)  (99%)  (1%)  (83%)  (17%)  
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 Female 
 




 Age  BMI  Tobacco  Alcohol  Menopause 
 Me  95%CI  Me  95%CI  No  Yes  Rare  Yes  No  Yes  ? 
 Hong Kong  132  121  39  21 – 58  21.1  17.5 – 28  117  4  118  3  106  15  0 
        (97%)  (3%)  (98%)  (2%)  (88%)  (12%)  
 HCMC  170  166  33  22 – 53  20.1  17 – 25.9  165  1  162  3  152  13  1 
        (99%)  (1%)  (98%)  (2%)  (92%)  (8%)  
 Kuala Lumpur  104  88  31  21 – 59  21.1  16.8 – 27.7  87  1  84  1  71  11  6 
        (99%)  (1%)  (99%)  (1%)  (87%)  (13%)  
 Jakarta  72  70  39  21 – 60  21.7  17.4 – 26.9  69  1  70  0  55  15  0 
        (99%)  (1%)  (100%)  (0%)  (79%)  (21%)  
 Sum  1959  1876  36  21 – 59  20.4  16.8 – 26.7  1782  81  1435  426  1536  296  44 
        (96%)  (4%)  (77%)  (23%)  (84%)  (16%)  
  3541           
 CI, confidence intervals; Me, median; No, the number of subjects before the secondary exclusion; N, the number of subjects after the 
secondary exclusion. 
of the reference individuals, whereas the remainder did 
not provide information on their job. 
 Standardization of test results 
 Excellent linearity between the test results and the values 
assigned to the reference materials with correlation coef-
ficients very close to 1.0 were obtained for all the analytes 
that were measured in three or more levels ( Supplemen-
tary Figure 1 ). The major axis regression was used to 
compute the regression line for recalibration. The results 
of reference materials measured at only a single level were 
used for recalibration by taking their ratio to the assigned 
values (Supplementary Table 2). 
 Sources of variations and 
regionality of results 
 The result of the 3N-ANOVA for all the analytes are sum-
marized in Table 2. The three factors analyzed were sex, 
region, and age. Those analytes indicated as  ‘ log ’ in the 
3rd column were transformed logarithmically before 
applying 3N-ANOVA. The level of SDR for sex (SDR sex ) was 
high (  ≥  0.3) for 19 analytes. In the table, the magnitude of 
between-sex difference quantified by 3N-ANOVA is com-
pared with that by the Harris-Boyd method [ 12 ,  13 ]. The 
two approaches agreed quite well in almost all analytes. 
The SDRs for region (SDR reg ) were high in five analytes: 
HDL-C, CRP, IgG, C3, and C4. SDRs for age (SDR age ) were 
high in 16 analytes. 
 Additionally, we noted unmatched regionality 
between the two sexes when we applied the 3N-ANOVA 
separately for males and females using the entire dataset, 
with inclusion of BMI as the third factor. The SDR reg   com-
puted for six analytes (urea, TG, IgA, IgM, Tf, and TTR) 
exceeded 0.3 only in either of the sexes (also shown in 
Supplementary Table 3A). As a whole, SDR reg of 11 analytes 
exceeded 0.3 in either or both of the sexes. This finding 
implies the importance of separate analysis for both sexes 
to clearly identify regionality by use of 3N-ANOVA. When 
data was limited to those obtained from Japan (Supple-
mentary Table 3B), there were no analytes that showed 
an SDR of   ≥  0.3. Examples of regional differences for eight 
analytes with a high SDR reg score (urea, HDL-C, IgG, IgA, 
C3, C4, and CRP, and Tf) are illustrated in  Figure 1 . Similar 
figures for the entire group of results including the items 
from questionnaires are also available on-line as  Supple-
mentary Figure 2 . 
 Reference intervals 
 RIs were derived from the reference individuals after the 
selection process in three ways: male plus female, male 
only, and female only, and by use of the modified Box-Cox 
formula. On the basis of the above results on regionality, 
when SDR reg was   ≥  0.25, RIs were computed in four ways: 
all Asians, Japanese, Chinese (Beijing + Taiwan + Hong 
Kong + Macau), and Southeast Asians (Ho Chi Minh 
City + Kuala Lumpur + Jakarta); otherwise, RIs were computed 
from the entire dataset (all Asians), as listed in  Table 4 . 
 In the derivation of RIs, we applied the tertiary exclu-
sion procedure based on the LAVE method.  Approximately 
13% of the original data were excluded (3314 → roughly 2880 
individuals) by the iterative optimization process. The effect 
of this tertiary exclusion was apparent only for analytes 
(Table 3 Continued)
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 Figure 1   Examples of regional differences in test results observed in eight analytes. 
 Each panel consists of two figures, one for males (left) and one for females (right). Test results were sub-grouped into 14 areas: seven from 
Japan (blue, male; red, female) and another seven from East and Southeast Asia (green, male; orange, female). The regions were aligned 
from north to south. The box within each scattergram represents the central 50% range, and the vertical line in the middle of the box indi-
cates the median. SDR reg displayed on top of each panel represents SD ratio of between-region variations to the pure between-individual 
variation. SDR > 0.3 was considered as practically significant. 
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 Table 4   List of RIs derived. 
 International Unit  SDR-reg  Area 
 n 
 Male  + Female  
 n 
 Male  
 n 
 Female 
 Analytes, Units  LL  Me  UL  LL  Me  UL  LL  Me  UL 
 Alb, g/L  0.00  Asia All  2920  41  45  51  1298  41  46  51  1626  40  45  50 
 Urea, mmol/L  0.24  Asia All  2888  2.7  4.4  7.1  1277  2.9  4.7  7.3  1608  2.6  4.1  6.8 
 UA, μmol/L  0.19  Asia All      1293  223  347  471  1629  153  240  344 
 CRE, μmol/L  0.24  Asia All      1276  61.0  76.7  97.0  1611  41.9  55.8  70.6 
 Na, mmol/L  0.00  Asia All  2886  139  142  146  1277  140  143  146  1606  139  142  145 
 K, mmol/L  0.23  Asia All  2872  3.7  4.2  4.7  1270  3.7  4.2  4.7  1604  3.6  4.1  4.7 
 Cl, mmol/L  0.00  Asia All  2889  101  104  108  1277  100  104  108  1611  101  104  108 
 Ca, mmol/L  0.00  Asia All  2887  2.19  2.33  2.47  1276  2.21  2.35  2.49  1611  2.18  2.31  2.45 
 TCho, mmol/L  0.00  Asia All  2889  3.47  4.85  6.73  1278  3.49  4.85  6.74  1611  3.48  4.83  6.80 
 TG, mmol/L  0.27  Asia All  1551  0.41  0.81  2.20  588  0.49  1.00  2.77  961  0.39  0.73  1.67 
   Japanese  1307  0.41  0.73  1.72  474  0.47  0.90  2.18  836  0.39  0.66  1.40 
   Chinese  538  0.41  0.84  2.12  216  0.55  1.02  2.80  312  0.43  0.77  1.91 
   SE Asia  422  0.47  0.99  3.05  159  0.53  1.24  3.38  252  0.50  0.87  2.50 
 HDL-C, mmol/L  0.57  Asia All  2915  0.94  1.52  2.43  1283  0.89  1.34  2.11  1628  1.07  1.67  2.55 
   Japanese  1748  1.04  1.63  2.54  790  0.99  1.44  2.27  955  1.19  1.78  2.64 
   Chinese  596  0.95  1.40  2.25  268  0.85  1.24  1.81  336  1.02  1.56  2.32 
   SE Asia  483  0.85  1.28  2.10  197  0.81  1.11  1.61  285  0.98  1.43  2.24 
 LDL-C, mmol/L  0.00  Asia All  1561  1.65  2.83  4.55  594  1.83  2.94  4.85  969  1.62  2.75  4.46 
 AST, U/L  0.12  Asia All  1872  14.4  21.0  32.3  803  15.8  22.8  34.8  1064  14.3  20.0  29.4 
 AST-JSCC, U/L  –  Japanese  1715  15.2  21.3  30.8  769  16.1  22.9  32.9  953  14.7  20.3  28.0 
 ALT, U/L  0.12  Asia All  1562  11.5  19.5  43.6  591  13.7  23.9  54.0  973  10.6  17.6  31.0 
 ALT-JSCC, U/L  –  Japanese  1280  10.5  16.8  32.6  467  12.0  20.5  40.7  826  10.2  15.4  26.5 
 LD, U/L  0.08  Asia All  2924  138  181  235  1291  142  184  240  1634  136  178  233 
 LD-JSCC, U/L  –  Japanese  1730  124  165  215  783  127  168  220  945  123  162  209 
 ALP-JSCC, U/L  0.15  Asia All  2873  34  56  90  1272  39  61  96  1604  32  52  84 
 GGT, U/L  0.01  Asia All  1526  14  21  49  588  15  27  68  959  15  19  43 
 GGT-JSCC, U/L  –  Japanese  1283  14  20  54  470  15  25  66  819  15  19  44 
 CK, U/L  0.11  Asia All  2912  43  89  226  1280  58  116  261  1619  40  74  152 
 CK-JSCC, U/L  –  Japanese  1712  42  86  192  781  60  108  263  938  40  71  135 
 AMY, U/L  0.11  Asia All  2876  47  80  136  1273  45  77  131  1604  51  82  148 
 IgG, g/L  0. 38  Asia All  2885  9.2  12.9  18.8  1274  8.8  12.4  18.0  1610  9.5  13.3  19.1 
   Japanese  1728  9.0  12.5  17.8  769  9.0  12.1  17.2  948  9.4  12.9  18.3 
   Chinese  595  9.8  13.0  18.8  264  9.5  12.6  18.2  332  9.8  13.4  18.6 
   SE Asia  478  10.8  14.7  21.7  190  10.8  14.1  21.5  283  11.4  15.1  21.8 
 IgA, g/L  0. 27  Asia All  1270  1.06  2.22  4.33  561  0.93  2.22  4.19  709  1.02  2.21  4.26 
   Japanese  1077  0.94  2.12  3.96  491  0.99  2.23  4.13  583  0.95  2.04  3.80 
   Chinese  390  1.02  2.34  4.51  171  1.01  2.34  4.39  219  1.10  2.38  4.59 
   SE Asia  354  1.09  2.32  4.29  158  1.24  2.27  4.31  195  1.18  2.40  4.65 
 IgM, g/L  0.17  Asia All  2869  0.37  1.06  2.38  1267  0.33  0.84  1.78  1603  0.49  1.26  2.65 
 C3, mg/L  0.47  Asia All  2875  729  1007  1389  1286  757  1036  1427  1586  716  983  1352 
   Japanese  1727  715  971  1301  771  738  1000  1345  954  708  946  1261 
   Chinese  593  773  1064  1414  264  802  1086  1438  326  786  1040  1431 
   SE Asia  470  798  1128  1526  198  819  1158  1569  270  796  1107  1475 
 C4, mg/L  0.41  Asia All  2857  122  201  340  1271  122  205  339  1601  112  192  339 
   Japanese  1725  113  188  308  780  120  198  313  942  109  180  293 
   Chinese  598  129  208  383  267  132  214  368  331  123  207  371 
   SE Asia  478  132  237  394  196  137  244  408  281  141  232  404 
 CRP, mg/L  0.42  Asia All  2849  0.01  0.38  2.81  1247  0.04  0.43  3.74  1590  0.01  0.30  2.57 
   Japanese  1223  0.06  0.25  2.50  458  0.09  0.28  2.44  820  0.02  0.29  2.59 
   Chinese  522  0.11  0.46  5.87  214  0.12  0.57  5.86  308  0.10  0.42  4.74 
   SE Asia  417  0.11  0.71  5.71  156  0.12  0.85  4.92  260  0.11  0.61  6.66 
 TTR, mg/L  0.24  Asia All  2889  193  271  391  1278  230  308  401  1612  186  246  331 
 Tf, g/L  0. 26  Asia All  2880  1.91  2.52  3.47  1271  1.88  2.42  3.10  1604  2.00  2.62  3.60 
   Japanese  1717  2.01  2.58  3.52  775  1.99  2.48  3.18  941  2.04  2.68  3.66 
   Chinese  600  1.84  2.45  3.33  267  1.76  2.36  2.95  330  1.97  2.56  3.50 
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 International Unit  SDR-reg  Area 
 n 
 Male  + Female  
 n 
 Male  
 n 
 Female 
 Analytes, Units  LL  Me  UL  LL  Me  UL  LL  Me  UL 
   SE Asia  478  1.90  2.41  3.23  195  1.86  2.28  2.94  283  1.99  2.50  3.40 
 Testo, nmol/L  0.00  Asia All      1269  10.1  17.4  28.4  1609  0.9  2.0  3.5 
 Estradiol, pmol/L  0.00  Asia All      1266  66  96  140  1609  50  198  840 
 Progest, nmol/L  0.00  Asia All      1265  0.37  1.69  4.48  1610  0.1  3.7  66.5 
 Cortisol, nmol/L  0.21  Asia All  2876  45  100  193  1274  51  109  197  1605  41  92  190 
known to be related to the metabolic syndrome (TG, AST, 
ALT, GGT, and CRP) (Supplementary Table 4). For these 
five analytes, individuals consuming ethanol  > 40 g/day 
and those with BMI  > 26 kg/m 2   were excluded before deriv-
ing RIs. In addition, in derivation of RIs for IgA, individu-
als who reported presence of allergic conditions (allergic 
rhinitis, atopic dermatitis, etc.) in the questionnaire were 
excluded before the computation. Therefore, the number of 
reference individuals for those analytes was smaller. 
 As supplementary information, RIs were computed in 
total of seven ways (additionally for Taiwan, Hong Kong/
Macau, and Ho Chi Minh City), irrespective of SDR reg values, 
in both international and conventional units as listed in 
Supplementary Table 5. Age-related reference intervals for 
every 10 years of age for each sex were derived both from 
data of the entire regions and from data limited to Japan, 
and were provided as Supplementary Table 6A and B. 
 Discussion 
 To avoid the potential influence of differences in occu-
pation on test results, we recruited candidate reference 
individuals mostly from healthy hospital workers (84%), 
with the remainder from those who worked indoors. This 
recruitment policy may give an impression of bias in the 
population. However, there are a variety of jobs in medical 
facilities, and the level of physical activity differs widely 
from one individual to another. Therefore, we believe that 
the target population actually represents a majority of the 
general population working mostly indoors. However, 
if we had sampled more broadly, we could not have dis-
tinguished true regional differences from those attribut-
able to occupational environment and degree of labor. To 
assess the practicality of the RIs derived, further investiga-
tion may be required in each geographical area to compare 
the RIs with those derived based on data obtained in a 
setting of community health screening. 
 In defining reference individuals, it is also important 
to clarify a policy regarding how to exclude those with 
abnormal results due to latent diseases. Although there 
are many pathological conditions that may affect the test 
results of each analyte, we assumed that as long as the 
prevalence was low, inclusion of results from such cases 
would not have any influence on the determination of 
RIs targeting the central 95% interval. In contrast, careful 
consideration must be given to the exclusion of those 
individuals with latent but highly prevalent disorders like 
metabolic syndrome and diabetes. For excluding abnor-
mal results, it is not appropriate to apply clinical decision 
limits (CDL), generally set by consensus among clinical 
experts as a guide for prevention of those diseases. Such a 
univariate approach of excluding abnormal values results 
in truncation of the reference distribution. 
 To exclude individuals with abnormal results due to 
latent diseases, we applied a multivariate approach called 
the LAVE method [7,  9 ,  13 ,  14 ], which is an iterative method 
for optimized selection of reference individuals. In the 
initial iteration, it determines RIs analyte by analyte in 
a univariate manner without consideration of other test 
results. From the second iteration on, a RI for any given 
analyte is computed from datasets after excluding the 
values of individuals who have abnormal results in other 
analytes. By repeating this process, the RIs are progres-
sively optimized so long as there are associations among 
the abnormal results. This method applies a principle 
similar to the one presented by Grossi et al. [ 16 ] based on 
the correlation among variables. In the present study, we 
used the RIs of 13  ‘ basic ’ analytes as criteria in judging the 
need for exclusion: Alb, Glb, UA, Glu, AST, ALT, LD, GGT, 
CK, TG, HDL-C, LDL-C, and CRP. The LAVE method effec-
tively narrows the RI when there are associations with test 
results of the  ‘ basic ’ analytes set for exclusion criteria (see 
Supplementary Table 4), whereas RIs of analytes that lack 
such association are not affected. The LAVE method also 
does not cause any change in RIs of analytes for which 
abnormal results are rare among healthy individuals, 
(Table 4 Continued)
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such as Alb, CRE, urea, and Na. As expected, for the ana-
lytes in the lipid profile, the obtained results were differ-
ent from the CDL, which have a different origin and are 
usually aimed at a specific group of diseases [ 17 ]. 
 The most conspicuous finding of this study was the 
detection of no regionality in test results for any of the 31 
analytes examined within the entire area of Japan. This 
implies that it is possible to share RIs nationwide in Japan 
for the standardized analytes that were made traceable 
to a reference measurement system. In contrast, when 
all Asian areas were included in the nested ANOVA, we 
observed apparent regional differences in five analytes: 
HDL-C, IgG, C3, C4, and CRP. In regard to inflammatory 
markers, we reproduced and confirmed the findings of the 
past two Asian studies [ 7 ,  9 ]: the closer the regional area 
is to the equator, the higher the serum concentrations of 
positive inflammatory markers (IgG, C3, CRP). This same 
tendency was also found for C4. It is assumed that expo-
sure to infectious agents is higher in regions closer to the 
equator. 
 We were not able to identify the reason for the promi-
nent difference in the level of HDL-C between Japan and 
the rest of the regions by use of 3N-ANOVA in the second 
Asian study. However, when we re-analyzed this sepa-
rately for both sexes, we detected apparent regionality 
(SDR reg   ≥  0.3) with the same tendency for both sexes: 
higher HDL-C levels in two cities in Japan compared with 
four other cities. However, the regionality detected in elec-
trolytes (Na, K, Cl, and Ca) and LD in the second study was 
not clearly observed this time, although there was a slight 
tendency for local differences in K and LD from the graph. 
The much smaller data size in the second study may have 
been responsible for the inconsistent results. This result 
poses a question as to the appropriateness of the cut-off 
value for SDR set at 0.3. In fact, when the SDR reg was com-
puted after separating the dataset by sex, regionality with 
a SDR reg of   ≥  0.3 was observed in either or both of the sexes 
in 11 analytes, an increase of six analytes after the sepa-
ration. Those analytes showing regionality only in males 
were urea, IgM, TTR, and Tf, and those with regionality 
only in females were TG and IgA. Furthermore, when we 
looked at the graphs (Supplementary Figure 2) showing 
the regional distributions, some of the test results showed 
a bias limited to just one or two areas. For example, test 
results for LD are lower in Kuala Lumpur and Jakarta, and 
those for ALP are higher in these two cities than elsewhere. 
Therefore, even when SDR reg is well below 0.3, presence of 
localized bias in test results cannot be denied completely. 
We must also note that the number of volunteers recruited 
within Japan was much larger than that outside Japan, 
and there was no regionality within Japan. Therefore, 
this imbalance inevitably caused dilution of the effect of 
regional differences. 
 To adjust for regional differences in BMI and smoking 
and drinking habits, we applied multiple regression analy-
ses and confirmed that none of the regionality observed in 
test results was influenced by the covariates. These results 
will be reported in the companion article to be published 
in this series. 
 Although we emphasized the presence of regionality in 
the above discussion, we could derive  ‘ common ’ RIs valid 
at least in Southeast Asian countries for the majority of the 
analytes. As we made the test results traceable to the refer-
ence measurement procedures through careful recalibration 
using certified reference materials, the RIs are in a sense 
 ‘ universal ’ as long as the constitution of the target popula-
tion and the statistical methodologies do not change. 
 From the standpoint of traceability, we could make a 
valid comparison of our results with RIs for AST, ALT, and 
GGT made traceable to a reference measurement system 
that was recently derived by the IFCC C-RIDL targeting 
European and Asian population [ 6 ]. 
 In conclusion, RIs which can be applicable to a 
wide geographical area in Asia were established for 
the  majority of analytes with traceability to reference 
measuring systems, whereas regional partitioning was 
required for RIs of HDL-C, CRP, IgG, C3, and C4 in both 
sexes and for urea, TG, IgA, IgM, Tf, and TT in either 
of the sexes. However, no regional differences were 
observed in any analyte when data were limited to those 
from Japan. 
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